Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary Endpoint

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary Endpoint The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A